Month: September 2025

PITTSBURGH, Sept. 11, 2025 (GLOBE NEWSWIRE) — L.B. Foster Company (Nasdaq: FSTR, the “Company”), announced today that John Kasel, President and Chief Executive Officer, and Bill Thalman, Executive Vice President and Chief Financial Officer, will present virtually at the Sidoti Small Cap Virtual Conference on September 18, 2025, beginning at 9:15 AM ET. Presentation materials for the conference will be posted on the Company’s Investor Relations website under “Presentations” the morning of the conference. A video webcast and a video replay will be available online. A webcast registration link will be available on the L.B. Foster website: www.lbfoster.com, under the Investor Relations page, on the day of the event. Video replay will remain available for 90 days. About L.B. Foster CompanyFounded in 1902, L.B. Foster Company is a global...

Dayforce recognized for Ability to Execute and Completeness of Vision MINNEAPOLIS and TORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced it has been named a Leader in the 2025 Gartner Magic Quadrant for HCM Suites for 1,000+ Employees Enterprises. Dayforce was recognized for the sixth consecutive year, driven by Dayforce’s Ability to Execute and Completeness of Vision. Operating across North America, Europe, the Middle East, Africa (EMEA), and Asia-Pacific and Japan (APJ), Dayforce delivers quantifiable value to organizations globally with a single AI-powered people platform for HR, Pay, Time, Talent, and Analytics. Dayforce is trusted by more than 6,980 customers, including leading organizations such as OTG...

Total number of shares and voting rights in the share capital as of August 31, 2025 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date  Total number of shares in the capital   Number of theoretical voting rights  Number of exercisable voting rights 08/31/2025  131 318 716 223 422 497 223 021 474Next on the agenda: Third Quarter (Q3) 2025 turnover, October 22, 2025 (after market close)About Voltalia (www.voltalia.com)Voltalia is an international player in the renewable energy sector. The Group produces and sells electricity generated from wind, solar, hydraulic, biomass and storage facilities that it owns and operates. Voltalia has generating capacity in operation and under construction of more than 3.3 GW and a portfolio of projects...

ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 – 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) increased by 39% to DKK 258.0 million. The positive revenue performance reflected an increase in sales of both instruments, consumables and services. The launch of the new XcytoMatic products is proceeding as planned. “Along with our strong focus on creating renewed momentum in our existing business, we spent considerable resources during the financial year on launching our new high-tech XcytoMatic products. The launch of the XcytoMatic 40 is paving the way for ChemoMetec in the bioprocessing market, while the new XcytoMatic 30 and 50 instruments, both of which were developed on the same technology platform as the XcytoMatic...

ANNOUNCEMENT NO. 291 11 September 2025Guidance for the 2025/26 financial year  ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2025/26 (p. 39-40).Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments...

The esteemed ranking celebrates ASUS for outstanding performance in employee satisfaction, revenue growth, and sustainable practices KEY POINTSTIME recognition: ASUS secures its second inclusion on TIME’s World’s Best Companies that set the standard in innovation, growth, employee satisfaction A commitment to innovation: ASUS validated for its leadership in fostering a great workplace, driving business growth, and advancing sustainability Global distinction: ASUS continues to receive worldwide acclaim from esteemed organizations like Fortune, Forbes, and NewsweekTORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) — ASUS today announced its second appearance in TIME magazine’s prestigious list of the World’s Best Companies. This accolade recognizes organizations that set the standard in employee satisfaction, revenue growth, and sustainability...

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Paris, France (September 11, 2025 – 6:00 pm) – As of August 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.  August 31, 2025Shares outstanding 463,145,529Number of real voting rights (excluding treasury shares) 461,157,737Theoretical number of voting rights (including treasury shares) 463,145,529It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article...

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell CancerA total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line treatment for metastatic Non-Small Cell Lung Cancer following first-line chemo-immunotherapy. Top-line results expected in the second half of 2026.NANTES, France – ROME, Italy – September 11, 2025, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotechnology company focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, and the FoRT Foundation (Fondazione...

RELEASE Paris, September 11, 2025 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITALIn accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from those previously published.Date Total number of shares Total number of theoretical voting rights (including treasury stock) Total number of effective voting rights (exercisable at shareholders’ meetings) Publications31 August 2025 105 569 412 179 545 613 178 811 721 11 September 202531 July 2025 105 569 412 179 550 181 178 816 459 11...